|
Tuesday 14th October 2008
|
8.30am | Registration and welcome coffee
|
8.50am | Opening remarks and welcome from the Chair
Prof Robert Booy, Co-Director, National Centre for
Immunisation Research and Surveillance
|
| A GLOBAL PERSPECTIVE AND LOCAL MARKET OUTLOOK |
|
9am | The new era of adjuvant systems
- Broadening vaccine development beyond antigen research to adjuvanted products
- A new generation of more powerful adjuvants
- Identifying the benefits of rapid induction and dose sparing
capability delivered in pandemics
Dr Su-Peing Ng, Director, Clinical R & D and Medical Affairs Australasia, GlaxoSmithKline
|
9.25am | The ongoing revolution in global vaccinology
- Developing global vaccine approaches for global immunisation needs
- Overcoming the obstacles to the development and global
distribution of vaccines
- What does the future hold for international immunisation
programs?
Sir Gustav Nossal, Chair Strategic Advisory Council,
Children’s Vaccine Program, PATH
|
9.50am | Industry expert panel session: Comparing the Australian market to the global vaccine economy
- Analysing the local market size, drivers and growth dynamics
- Which vaccines present the greatest investment opportunities in Australia?
- Leveraging Australia’s position as a global leader in conducting clinical trials
Andrew Goodsall, Senior Healthcare Analyst, UBS
Rob Gallagher, Healthcare Analyst, Macquarie Capital
|
10.30am | Morning tea and Speed Networking
|
| OPPORTUNITIES AND CHALLENGES INVACCINE FUNDING |
|
11.30am | Supporting global health through sustainable
immunisation financing
- Helping governments secure long-term, sustainable immunisation financing
- Improving access and increasing R&D through public-private
partnerships
- Coordinating sector efforts to stimulate vaccine development
Dr Hannah Kettler, Director Global Health Policy & Advocacy, Gates Foundation
|
11.55am | Investing in vaccines for developing countries: ethical
partnering for profitability
- Examining the profitability of investing in developing countries
- Analysing efforts to incentivise the industry
- Which is the most successful approach?
Dr Mansour Yaich, Vaccine Development Director, PATH
|
12.20pm | Panel session: Investing in orphan vaccines
- Why is the industry hesitant to invest in orphan vaccines?
- Incentivising the development of orphan vaccines
- Examining legislation designed to overcome the disincentives
to developing orphan vaccines
Dr MansourYaich, Vaccine Development Director, PATH
Dr Hannah Kettler, Director Global Health Policy & Advocacy, Gates Foundation
Dr Satish Ravetkar, Senior Director, Serum Institute of India
|
1pm | Networking lunch
|
| GOVERNMENT, POLICY AND REGULATORY ISSUES |
|
2pm | National immunisation KOLs panel session: Designing the best national immunisation strategy
- Reviewing Immunise Australia Program updates
- Streamlining the process of introducing novel vaccines to
National Immunisation Schedule
- Maintaining the high level of public access to vaccines in the
Australian market
Andrew Pengilley, Medical Advisor, Office of Health Protection, Dept. of Health and Ageing
Assoc Prof Rajiv Khanna, Director, Australian Centre for Vaccine Development
Prof David Isaacs, Member, ATAGI and PBAC
|
2.45pm | Implementing a whole-of-life vaccine registry
- Why do we need a national adult vaccination registry?
- Including a vaccine adverse event reporting system in the
registry
- Incorporating unique identifiers, a national product catalogue
and shared e-health records
Karen Gibson, General Manager, National E-Health
Transition Authority
|
3.10pm | Policy considerations for adult vaccines in Australia
- Examining the gaps in the Australian National Immunisation Schedule presented by adult vaccines
- Incorporating boosters and adult vaccines into the Australian
immunisation strategy
- Implications of adult vaccines for a whole-of-life registry
Wyeth representative
|
3.35pm | Introducing a new vaccine to the Australian market
- Identifying the distinctions of the Australian regulatory landscape
- Examining the entry challenges faced in Australia
- Overcoming increasing costs and regulatory complexity
Dr Jane Leong, Medical Director, CSL Biotherapies
|
4.05pm | Afternoon tea
|
| BUILDING PARTNERSHIPS AND EVOLVING BUSINESS MODELS
|
|
4.30pm | Partnering for success: The vaccine development model
- How can small biotechs and big pharma work together to produce vaccines quickly and economically?
- Engaging as a research partner as opposed to a mere investor
- What is the optimal stage in the development process to
partner?
Dr Daniel Grant, Head Strategic Alliances ANZ, Pfizer
|
4.55pm | Adopting a partnership and exchange approach with
overseas companies
- Collaborating with overseas manufacturers to streamline vaccine production
- How to partner with offshore companies in a technology
transfer relationship
- Examining the benefits of importing vaccines in an epidemic
Dr Satish Ravetkar, Senior Director, Serum Institute of India
|
5.20pm | Biotech innovators panel: Building a successful product portfolio: innovating for future growth
- Balancing vaccine development portfolios to maximise profitability whilst minimising risk
- Developing a sustainable R&D pipeline delivering the optimal
cost-effective vaccines
- Proactively identifying targets for a global portfolio
Dr Andrew O’Brien, MD, BioDiem
Dr Mark Radford, CEO and MD, Symbiosis Group
Dr Martin Soust, MD, SelectVaccines
|
6pm | End of Day One and networking drinks
|
|
Wednesday 15th October 2008
|
8.30am | Welcome coffee
|
8.50am | Opening remarks and welcome from the Chair
Assoc Prof Rajiv Khanna, Director, Australian Centre for Vaccine Development
|
| THE NEXT GENERATION OFVACCINES |
|
9am | Is there a viable future for DNA vaccines?
- Examining the current state of DNA vaccines
- Do recent findings spell the end for DNA vaccines?
- Laying future directions for DNA vaccines research
Dr Jeffrey Ulmer, Global Head of External Research, Novartis
|
9.30am | Developing a universal influenza vaccine
- Is a universal influenza vaccine within reach?
- Reviewing global approaches
- Examining the latest results from human trials of the M2ebased
vaccine
Dr Ian Barr, Deputy Director, WHO Centre for Influenza
|
10am | Therapeutic immunisation: where are we heading?
- Therapeutic vs. prophylactic vaccines: where does the future of the vaccine market lie?
- Enhancing responses to multidrug therapy and reducing
frequency of relapses
- Therapeutic vaccines for HIV, hepatitis B, malaria,
tuberculosis and autoimmune diseases
Dr Ian Frazer, Director, Diamantina Institute for Cancer
|
10.30am | Morning tea
|
| AN UPDATE OF GLOBALVACCINE PRIORITIES |
|
11am | Examining avian flu pandemic strategies
- Collaborating between stakeholders to ensure seasonal and pandemic influenza vaccine supply
- Utilising emerging vaccine technologies to speed up influenza
vaccine production in a pandemic
- How ready are we for an avian flu pandemic?
Dr Klaus Stohr, Director, Influenza Vaccine Franchises, Novartis
|
11.25am | Accelerating malaria vaccine development
- Examining the latest developments in malaria vaccines research
- Developing a global vaccine approach for a global
immunisation priority
- How can public and private sectors work together to
overcome scientific and economic challenges?
Dr Christian Loucq, Director, PATH MalariaVaccine Initiative
|
11.50am | Developing a therapeutic Hepatitis C vaccine
- Examining the latest results from clinical trials: towards a proof-of-concept in patients
- Including IC41 as an adjuvant in prophylactic Hepatitis
vaccinations
- Utilising results to develop a prophylactic Hep C vaccine
Christoph Klade, Vice President Technology Development & Clinical Immunology, Intercell AG
|
12.15pm | Updating developments in AIDS vaccine research
- Identifying the most promising vaccines in clinical trials
- Coordinating R&D efforts across multiple research centres
- Working together in developing an AIDS vaccine
Dr Ian Gust, Chair Scientific Advisory Board, International AIDS Vaccine Initiative
|
12.40pm | Networking lunch
|
1.40pm | New paradigms and market opportunities in use of novel
adjuvants to rejuvenate old vaccines
- Utilising new adjuvants to protect patents on old vaccines
- Overcoming the regulatory issues of increased reactogenicity
- Considering the impact of emerging adjuvants on vaccine
development
Prof Nikolai Petrovsky, Chairman, Vaxine
|
| DEVELOPMENTS IN DELIVERY SYSTEMS AND ADJUVANTS |
|
2.05pm | Examining the benefits of vaccine patch technology
- Identifying the applications of patch delivery systems: epidemics, travellers and the chronically ill
- Comparing immune responses elicited by patch vs. traditional
administration
- Using patches to deliver otherwise undeliverable adjuvants
Stanley Erck, President and CEO, Iomai Corporation
|
2.30pm | Investing in mucosal immunisation: the path to product
- Examining the latest clinical research into mucosal delivery systems
- Understanding the difficulties in developing a commercially
viable mucosal immunisation strategy?
- Identifying which vaccines will be best delivered by mucosal
routes
Prof Allan Cripps, Pro Vice Chancellor Health, Griffith
University
|
2.55pm | Afternoon tea
|
| STREAMLINING VACCINE PRODUCTION AND DISTRIBUTION FOR
THE FUTURE |
|
3.20pm | Learning lessons from the EI outbreak: vaccine selection,
acquisition, and delivery in an emergency
- Preparing for emergency outbreaks by ensuring availability
- Collaborating with manufacturers to ensure steady supply
- Managing the cold chain for quality and reliability
- Using a GM product: auditing and training considerations
Ian Denney, Manager Veterinary Services, Animal Health Australia
|
3.50pm | Innovative technologies to improve vaccine development
and production
- Analysis of traditional development and processing processes
- Process compression using innovative technologies in
clarification, ultrafiltration and fluid handling
- Advances in sterile processing of adjuvant and liposomal
preparations
- Increasing regulatory compliance and speeding process
development using disposable technologies
Michael Payne, Knowledge Development Manager, Millipore
|
4.15pm | Panel session: Future prospects for the global vaccines market
- Emerging threats to the global vaccines industry
- Future of government immunisation legislation
- Global strategies for the international markets
Dr Hannah Kettler, Director Global Health Policy & Advocacy, Gates Foundation
Dr MansourYaich, Vaccine Development Director, PATH
Prof Robert Booy, Co-Director, National Centre for
Immunisation Research and Surveillance
GlaxoSmithKline representative
|
5pm | Closing remarks and close of conference
|
